Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Fineline Cube Jun 24, 2026
Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Company Deals

Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Fineline Cube Jun 25, 2026
Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Fineline Cube Jun 25, 2026
Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for AK2024 in HER2 Positive Solid Tumors

Fineline Cube Jul 2, 2025

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) announced that it has received clinical...

Company Drug

Chengdu Kanghong Receives NMPA Approval for Clinical Trials of KH813 in Metastatic nsq-NSCLC

Fineline Cube Jul 2, 2025

China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) announced that it has received clinical...

Company Drug

Takeda Pharmaceutical Gains FDA Approval for Gammagard Liquid Erc in Primary Immunodeficiency

Fineline Cube Jul 2, 2025

Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that it has received marketing approval from...

Company Deals

3SBio Partners with Thermo Fisher to Advance Cell and Gene Therapy Solutions

Fineline Cube Jul 2, 2025

China-based 3SBio Inc. (HKG: 1530) announced last week a strategic partnership with US-based life sciences...

Company Drug

Jacobio Pharma Initiates First Patient Dosing in U.S. Phase I/IIa Study for Pan-KRAS Inhibitor JAB-23E73

Fineline Cube Jul 2, 2025

China-based Jacobio Pharma (HKG: 1167) announced the first patient dosing of a Phase I/IIa study...

Company Deals Digital

Shanghai Pharmaceuticals’ MediTrust Health Files for IPO in Hong Kong Amidst AI-Powered Healthcare Payment Transformation

Fineline Cube Jul 2, 2025

Shanghai Pharmaceuticals Holding Co., Ltd’s (SPH, HKG: 2607, SHA: 601607) subsidiary, Shanghai MediTrust Health Technology...

Company Drug

Hisun Pharmaceuticals Receives NMPA Approval for HS387 Clinical Trials in Advanced Solid Tumors

Fineline Cube Jul 2, 2025

China-based Zhejiang Hisun Pharmaceutical Co., Ltd (SHA: 600267) announced that it has received clinical trial...

Company Medical Device

China Isotope & Radiation Corporation Showcases C-14 Barium Carbonate at International Symposium

Fineline Cube Jul 2, 2025

China Isotope & Radiation Corporation (CIRC; HKG: 1763) announced that it showcased its C-14 barium...

Company Deals

Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio

Fineline Cube Jul 2, 2025

German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...

Company Drug

Allergan Aesthetics’ SKINVIVE by JUVÉDERM Accepted for FDA Review to Reduce Neck Lines

Fineline Cube Jul 2, 2025

Allergan Aesthetics, an AbbVie (NYSE: ABBV) company, announced that the supplemental premarket approval (sPMA) application...

Company Deals

Hybio and iCarbonX Enter CRDMO Service Pact and Strategic Investment to Advance Peptide Drug Pipeline

Fineline Cube Jul 2, 2025

This week, China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) and iCarbonX entered into an innovative...

Company Deals

EnChannel Medical Acquires AcQMap Platform Assets from Acutus Medical to Strengthen Non-Contact Mapping Tech

Fineline Cube Jul 2, 2025

Guangzhou-based electrophysiology platform company EnChannel Medical Ltd. is set to acquire the AcQMap High Resolution...

Company Deals

Jiangsu Hengrui Pharmaceuticals Partners with NSFC to Establish Private Enterprise Innovation Fund

Fineline Cube Jul 2, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced an agreement with the National...

Company Deals

Sanofi Invests $25 Million in China’s Adagene to Advance SAFEbody Program

Fineline Cube Jul 2, 2025

French pharmaceutical major Sanofi (NASDAQ: SNY) is set to make a USD 25 million investment...

Policy / Regulatory

NHSA Unveils Plans for 2025 National Drug List Adjustments and Commercial Insurance Drug List

Fineline Cube Jul 2, 2025

This week, China’s National Healthcare Security Administration (NHSA) released two draft documents detailing a plan...

Company Deals

Esteve to Acquire Sanofi’s Caprelsa Rights in Over 50 Countries for Medullary Thyroid Cancer Treatment

Fineline Cube Jul 2, 2025

Spanish multinational pharmaceutical company Esteve, which also operates an industrial site in China, is set...

Company Deals

AbbVie to Acquire Capstan Therapeutics for Its First-in-Class CAR-T Candidate

Fineline Cube Jul 1, 2025

US-based pharmaceutical giant AbbVie (NYSE: ABBV) is poised to acquire fellow American firm Capstan Therapeutics,...

Others

Chia Tai Tianqing’s Anlotinib Granted NMPA Approval for Soft Tissue Sarcoma

Fineline Cube Jul 1, 2025

China-based Chia Tai Tianqing Pharmaceutical announced that its anlotinib (trade name: FOCUS V) has received...

Company Drug

Huadong Medicine’s First-in-Class ADC HDM2012 Gains FDA Phase I Trial Clearance

Fineline Cube Jul 1, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clearance from the...

Policy / Regulatory

China Unveils Measures to Boost Innovative Drug Development With Insurance Data Support

Fineline Cube Jul 1, 2025

China’s National Healthcare Security Administration (NHSA) and National Health Commission (NHC) jointly released the “Several...

Posts pagination

1 … 155 156 157 … 687

Recent updates

  • Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients
  • Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications
  • AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six
  • YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders
  • Sanofi’s Wayrilz (Rilzabrutinib) Secures Japanese Approval for Immune Thrombocytopenia – Expanding Global Footprint Across Six Major Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Gilead’s Trodelvy (Sacituzumab Govitecan) Secures European Commission Approval for First-Line Metastatic TNBC – Expanding ADC Access to Treatment-Naïve Patients

Company Drug

Henlius and Organon Canada Launch Denosumab Biosimilars BILDYOS and TUZEMTY – Expanding Access to Bone-Targeted Therapies Across All Canadian Indications

Company Drug

AbbVie’s SKYRIZI (Risankizumab) Secures European Commission Approval for Pediatric Plaque Psoriasis – First IL-23 Inhibitor Authorized for Children as Young as Six

Company Deals

YHLO Biotech and Jingyi Bio Forge Strategic Alliance to Advance Neuroimmunology Diagnostics – Expanding Autoimmune Testing into Neurological Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.